EGFR and non-small cell lung carcinoma: Moreover, how to accurately identify the beneficiaries, the most appropriate mode and dose of immunotherapy plus antiangiogenic agents in treating advanced EGFR-mutated NSCLC patients represent issues that need to be further explored.